ClinicalTrials.gov Chelation Studies
1 | Completed | Combination Iron Chelation Therapy | ||||
Conditions: | Iron Overload; Thalassemia | |||||
Intervention: | Drug: Combination Iron Chelation Therapy | |||||
2 | Completed | Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency | ||||
Condition: | Urologic Disease | |||||
Intervention: | Drug: calcium disodium EDTA (edetate calcium disodium) | |||||
3 | Active, not recruiting | Penicillamine Chelation for Children With Lead Poisoning | ||||
Conditions: | Lead Poisoning; Vitamin D Deficiency | |||||
Interventions: | Device: d-penicillamine; Drug: placebo | |||||
4 | Active, not recruiting | An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload | ||||
Condition: | Transfusional Iron Overload in β-Thalassemia | |||||
Intervention: | Drug: Deferasirox | |||||
5 | Active, not recruiting | Mercury Chelation to Treat Autism | ||||
Conditions: | Autism; Asperger’s Disorder; Child Development Disorders, Pervasive | |||||
Intervention: | Drug: DMSA | |||||
6 | Active, not recruiting | Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload | ||||
Condition: | Transfusional Iron Overload in β-Thalassemia Major | |||||
Intervention: | Drug: Deferasirox | |||||
7 | Active, not recruiting | Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload | ||||
Condition: | Transfusional Iron Overload in Patients With Chronic Anemia | |||||
Intervention: | Drug: Deferasirox | |||||
8 | Active, not recruiting | Iron-Chelating Therapy and Friedreich Ataxia | ||||
Condition: | Friedreich Ataxia | |||||
Intervention: | Drug: Iron chelating intervention | |||||
9 | Completed | Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone | ||||
Conditions: | Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload | |||||
Intervention: | Drug: chelation therapy | |||||
10 | Completed | Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload | ||||
Condition: | Transfusional Iron Overload | |||||
Intervention: | Drug: Deferasirox | |||||
11 | Active, not recruiting | Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major | ||||
Condition: | Beta-Thalassemia | |||||
Intervention: | Drug: deferiprone | |||||
12 | Completed | CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients | ||||
Condition: | End Stage Renal Disease | |||||
Intervention: | ||||||
13 | Active, not recruiting | A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload | ||||
Condition: | Transfusion-Dependent Iron Overload | |||||
Intervention: | Drug: Deferasirox | |||||
14 | Active, not recruiting | Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload | ||||
Condition: | Transfusion-Dependent Iron Overload | |||||
Intervention: | Drug: Deferasirox | |||||
15 | Completed | Efficacy Study in Removing Excess Iron From the Heart | ||||
Conditions: | Thalassemia Major; Hemosiderosis | |||||
Interventions: | Drug: Ferriprox (deferiprone); Drug: Desferal (deferoxamine) | |||||
16 | Active, not recruiting | Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients | ||||
Conditions: | Myelodysplastic Syndrome; Iron Overload | |||||
Intervention: | Drug: Deferasirox | |||||
17 | Active, not recruiting | Cardiac Function in Patients With Hereditary Hemochromatosis | ||||
Condition: | Hemochromatosis | |||||
Intervention: | ||||||
18 | Active, not recruiting | A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis | ||||
Condition: | Sickle Cell Disease | |||||
Intervention: | Drug: Deferasirox | |||||
19 | Active, not recruiting | Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis | ||||
Condition: | Beta-Thalassemia Major | |||||
Intervention: | Drug: ICL670; deferasirox | |||||
20 | Completed | Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis | ||||
Condition: | Idiopathic Pulmonary Fibrosis | |||||
Intervention: | Drug: Tetrathiomolybdate | |||||
21 | Active, not recruiting | Treatment of Lead-Exposed Children Trial | ||||
Condition: | Lead Exposure | |||||
Intervention: | ||||||
22 | Completed | Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) | ||||
Conditions: | Beta Thalassemia; Hemoglobinopathy | |||||
Intervention: | Drug: Hydroxyurea | |||||
23 | Completed | 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia | ||||
Condition: | Beta Thalassemia | |||||
Intervention: | Drug: 5-Azacytidine | |||||
24 | Completed | Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis | ||||
Conditions: | Anemia (Iron-Loading); Beta-Thalassemia; Hematologic Diseases; Hemoglobinopathies; Thalassemia; Iron Overload; Hemochromatosis | |||||
Intervention: | Drug: deferoxamine | |||||
25 | Completed | Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN) | ||||
Conditions: | Anemia, Cooley’s; Beta-Thalassemia; Hematologic Diseases; Thalassemia; Osteoporosis; Iron Overload; Hypertension, Pulmonary | |||||
Interventions: | Drug: Deferoxamine; Drug: Deferiprone; Drug: Arginine; Drug: Sildenafil; Drug: Decitabine | |||||
26 | Active, not recruiting | Deferoxamine for the Treatment of Hemochromatosis | ||||
Conditions: | Diabetes Mellitus; Heart Disease; Hemochromatosis; Thalassemia | |||||
Intervention: | ||||||
27 | Completed | Monoclonal Antibody Therapy in Treating Patients With Leukemia | ||||
Conditions: | Lymphoma; Radiation Toxicity | |||||
Interventions: | Drug: pentetic acid calcium; Drug: yttrium Y 90 daclizumab; Procedure: monoclonal antibody therapy; Procedure: radioimmunotherapy; Procedure: radioprotection | |||||
28 | Completed | Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions | ||||
Condition: | Beta-Thalassemia | |||||
Interventions: | Drug: ICL670; Drug: deferoxamine | |||||
29 | Completed | Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias | ||||
Conditions: | Beta-Thalassemia; Myelodysplastic Syndromes; Fanconi Syndrome; Anemia, Diamond-Blackfan; Anemia, Aplastic | |||||
Intervention: | Drug: Deferasirox | |||||
30 | Completed | Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions | ||||
Condition: | Anemia, Sickle Cell | |||||
Interventions: | Drug: ICL670; Drug: deferoxamine | |||||
31 | Active, not recruiting | Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients | ||||
Conditions: | Sickle Cell Disease; Iron Overload; Hemolytic Anemia | |||||
Intervention: | Drug: Deferasirox | |||||
32 | Active, not recruiting | Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients | ||||
Conditions: | Myelodysplastic Syndromes; Iron Overload | |||||
Intervention: | Drug: deferasirox | |||||
33 | Completed | Chromium Picolinate for the Treatment of Metabolic Syndrome | ||||
Conditions: | Metabolic Syndrome X; Prediabetic State; Insulin Resistance; Obesity; Metabolic Diseases | |||||
Intervention: | Drug: Chromium picolinate | |||||
34 | Completed | A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis | ||||
Conditions: | Beta-Thalassemia; Hemosiderosis | |||||
Intervention: | Drug: deferasirox | |||||
35 | Active, not recruiting | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | ||||
Conditions: | Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia; Myelofibrosis | |||||
Intervention: | Drug: Deferasirox | |||||
36 | Completed | Chromium and Insulin Action | ||||
Condition: | Type 2 Diabetes | |||||
Intervention: | Drug: Chromium Picolinate | |||||
37 | Completed | Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM | ||||
Condition: | Diabetes Mellitus, Type 2 | |||||
Intervention: | Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg) | |||||
38 | Completed | Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-Dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine | ||||
Conditions: | Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Hib Disease | |||||
Interventions: | Biological: Pertussis vaccine; Biological: DTPa-HBV-IPV/Hib | |||||
39 | Completed | A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM | ||||
Condition: | Diabetes Mellitus, Type 2 | |||||
Intervention: | Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg) | |||||
40 | Completed | Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules | ||||
Conditions: | Healthy; Infant | |||||
Intervention: | Biological: DTPa-HBV-IPV/Hib vaccine | |||||
41 | Completed | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants | ||||
Conditions: | Diphtheria; Tetanus; Pertussis; Hepatitis B; Poliomyelitis; Haemophilus Influenza Type b Disease | |||||
Intervention: | Biological: DTPa-HBV-IPV/Hib vaccine | |||||
42 | Active, not recruiting | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine | ||||
Conditions: | Healthy; Infant | |||||
Intervention: | Biological: DTPa-HBV-IPV/Hib vaccine | |||||
43 | Terminated | Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes | ||||
Condition: | Type 2 Diabetes | |||||
Intervention: | Drug: Chromium Picolinate | |||||
44 | Active, not recruiting | Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients | ||||
Condition: | Hemochromatosis | |||||
Interventions: | Drug: Deferiprone (L1); Drug: Desferrioxamine | |||||
45 | Active, not recruiting | Iron-Fortified Whole Maize Flour Trial | ||||
Condition: | Anaemia | |||||
Intervention: | Drug: NaFeEDTA, Electrolytic Iron | |||||
46 | Completed | Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers | ||||
Condition: | Healthy | |||||
Interventions: | Drug: Deferasirox; Drug: Rifampicin | |||||
47 | Active, not recruiting | Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam | ||||
Condition: | Healthy | |||||
Intervention: | Drug: Deferasirox | |||||
48 | Active, not recruiting | Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA | ||||
Conditions: | Central Nervous System Tumors; Brain Tumors | |||||
Interventions: | Drug: Gallium-67 Citrate; Drug: In-111 DTPA | |||||
49 | Completed | Effects of Chromium Picolinate on Food Intake | ||||
Conditions: | Obesity; Atypical Depression | |||||
Intervention: | Drug: Chromium Picolinate | |||||
50 | Completed | An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients | ||||
Condition: | HIV Infections | |||||
Intervention: | Drug: Ditiocarb sodium |